A research breakthrough, funded by JDRF, has shown a promising future for the prevention of type 1 diabetes. Findings from a study by TrialNet show that the immunotherapy drug teplizumab can delay type 1 diabetes diagnosis a median of 2 years in children and adults at high risk. The study showed that teplizumab interferes with […]
The JDRF-led Type 1 Diabetes Clinical Research Network is currently recruiting for a study which could help reduce eye complications for people with type 1 diabetes. See full study details here, or email the FAME-1 study team at fame1eye@ctc.usyd.edu.au.